Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist administered via once-weekly subcutaneous injections, significantly improves glycemic control and reduces body weight in patients with type 2 diabetes and obesity compared to placebo, GLP-1 agonists, and basal insulin.
Tirzepatide is a once-weekly injection that activates two gut hormones (GIP and GLP-1) to help your pancreas release insulin when needed, slow down digestion, and reduce appetite. It is prescribed for type 2 diabetes and obesity. Clinical trials show it lowers blood sugar and body weight more effectively than many existing diabetes and weight-loss medications. Common side effects include nausea and diarrhea, which usually improve over time. It is taken alongside diet and exercise changes.
Tirzepatide is a new molecule capable of controlling glucose blood levels by combining the dual agonism of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors... Tirzepatide has been shown to improve blood pressure and to reduce Low-Density Lipoprotein (LDL) cholesterol and triglycerides.
Why this rating
Based on multiple phase III randomized controlled trials (SURPASS 1-5, SURMOUNT-1) and meta-analyses.
Source
Tirzepatide: A Systematic Update
Imma Forzano et al. · International Journal of Molecular Sciences · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →